AZ’ Imfinzi reduces risk of death by 32% in stage III NSCLC
AstraZeneca says Imfinzi is the first immunotherapy to show significant overall survival in a curative lung cancer treatment setting.
Read More
Tag: PACIFIC
Breakthrough status for AZ’ lung cancer drug Imfinzi
US regulators have granted AstraZeneca’s Imfinzi breakthrough status for the treatment of certain patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC).
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
